[A comparative study of the longacting neuroleptics perphenazin-enanthate and fluspirilene (author's transl)].
The clinical profile and side-effects of perphenazin-enanthate and fluspirilene were compared in 45 female chronic schizophrenic patients. 100 mg perphenazin-enanthate fortnightly or 8 mg fluspirilene weekly were administered. During the four months' period the psychopathological and somatic symptoms were evaluated by means of the AMP-system and the self-evaluation scale PD-S (v. Zerssen). A covariance analysis was carried out covering 12 AMP syndromes and 6 PD-S factors. The antipsychotic effect of both drugs was similar concerning the paranoid, the hallucinatory-desintegrative and the catatonic syndromes. A significant difference with regard to perphenazin-enanthate was found in the AMP-syndromes of hostility, hypochondria, and autonomic symptoms. Neither drug induced any depression. In the self-rating scale, the factors anxiousness and depressivity were also significantly lower in the perphenazin-enanthate regime. The patients under perphenazin-enanthate required a smaller amount of antiparkinsonian drugs. The more pronounced sedative effect of perphenazin-enanthate can be recommended in hostile and restless schizophrenic patients, whereas fluspirilene should be given to inactive autistic patients.
D002908:Chronic Disease; D003692:Delayed-Action Preparations; D005484:Fluspirilene / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D010546:Perphenazine / Q000008:administration & dosage / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D013141:Spiro Compounds / Q000627:therapeutic use*; D013997:Time Factors
D003692:Delayed-Action Preparations; D013141:Spiro Compounds; D005484:Fluspirilene; D010546:Perphenazine
Eine vergleichende Untersuchung der Depot-Neuroleptika Perphenazin Onanthat und Fluspirilen.